Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)

Trial Profile

Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms S-BR
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2017 Planned End Date changed from 1 Feb 2018 to 17 May 2017.
    • 18 May 2017 Planned primary completion date changed from 1 Feb 2018 to 17 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top